Guruprasad P Aithal
Overview
Explore the profile of Guruprasad P Aithal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
228
Citations
7101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Miller L, Halliday V, Snowden J, Aithal G, Lee J, Greenfield D
J Hum Nutr Diet
. 2024 May;
37(4):1007-1021.
PMID: 38696512
Background: Nutritional prehabilitation may improve haematopoietic cell transplantation (HCT) outcomes, although little evidence exists. The present study aimed to understand healthcare professional (HCP) perceptions of prehabilitation and nutritional care pre-HCT...
12.
Hirschfield G, Arndtz K, Kirkham A, Chen Y, Fox R, Rowe A, et al.
Hepatol Commun
. 2024 Apr;
8(5).
PMID: 38668724
Background: Primary sclerosing cholangitis is a progressive inflammatory liver disease characterized by biliary and liver fibrosis. Vascular adhesion protein-1 (VAP-1) is important in the inflammatory process driving liver fibrosis. We...
13.
Fuller A, Hancox J, Williams H, Card T, Taal M, Aithal G, et al.
Rheumatology (Oxford)
. 2024 Mar;
64(3):969-975.
PMID: 38483276
Objective: To explore the acceptability of an individualized risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s). Methods: Adults (≥18 years)...
14.
Huang A, Zhu Y, Liu S, Sun Y, Liu Z, Liang Q, et al.
Liver Int
. 2024 Mar;
44(6):1435-1447.
PMID: 38483145
Background And Aims: The use of corticosteroids in chronic drug-induced liver injury (DILI) is an important issue. Our previous randomized controlled trial showed that patients with chronic DILI benefited from...
15.
Abhishek A, Grainge M, Card T, Williams H, Taal M, Aithal G, et al.
RMD Open
. 2024 Mar;
10(1).
PMID: 38453215
Background: Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping monitoring after 1...
16.
Bonkovsky H, Ghabril M, Nicoletti P, Dellinger A, Fontana R, Barnhart H, et al.
Liver Int
. 2024 Mar;
44(6):1409-1421.
PMID: 38451034
Objective: To describe patients with NSAID-DILI, including genetic factors associated with idiosyncratic DILI. Methods: In DILIN, subjects with presumed DILI are enrolled and followed for at least 6 months. Causality...
17.
Bhala N, Subhani M, Aithal G
Lancet Gastroenterol Hepatol
. 2023 Nov;
8(12):1071.
PMID: 37951234
No abstract available.
18.
Astbury S, Baskar A, Grove J, Kaye P, Aravinthan A, James M, et al.
Endosc Int Open
. 2023 Nov;
11(10):E983-E991.
PMID: 37941539
Pancreatic cysts are common incidental findings, with an estimated prevalence of 13% to 15% in imaging done for other reasons. Diagnosis often relies on collection of cyst fluid, but tissue...
19.
Abhishek A, Stevenson M, Nakafero G, Grainge M, Evans I, Alabas O, et al.
Br J Dermatol
. 2023 Nov;
190(4):559-564.
PMID: 37931161
Background: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor...
20.
Pavlides M, Mozes F, Akhtar S, Wonders K, Cobbold J, Tunnicliffe E, et al.
Contemp Clin Trials
. 2023 Oct;
134:107352.
PMID: 37802221
Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome with global prevalence reaching epidemic levels. Despite the high disease burden in the population only a small...